Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease

Shomron Ben-Horin*, Matti Waterman, Uri Kopylov, Miri Yavzori, Orit Picard, Ella Fudim, Halim Awadie, Batia Weiss, Yehuda Chowers

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

275 Scopus citations

Abstract

There are few therapeutic options for patients with inflammatory bowel disease who lose response to infliximab because they produced antibodies against the drug. We performed a retrospective analysis to investigate whether administration of immune modulators to 5 patients who developed antibodies to infliximab (ATI) restored response to this drug; 3 patients were given azathioprine/6-mercaptopurine and 2 patients were given methotrexate. Concentrations of infliximab and ATIs, and antitumor necrosis factor (TNF) activity, were analyzed using enzyme-linked immunosorbent assay-based competition assays of serum samples collected before and after patients were given the immunomodulator. In all patients, levels of ATIs gradually decreased and trough levels of infliximab increased; clinical responses were restored to all patients. In competition assays, immunomodulator-induced elimination of ATIs was associated with increased anti-TNF activity in serum. The addition of immunomodulators to therapy might be helpful to patients who have lost response to anti-TNF agents owing to formation of antidrug antibodies.

Original languageEnglish
Pages (from-to)444-447
Number of pages4
JournalClinical Gastroenterology and Hepatology
Volume11
Issue number4
DOIs
StatePublished - Apr 2013

Funding

FundersFunder number
Sheba Medical Center

    Keywords

    • ADA
    • Crohn's Disease
    • IBD
    • Ulcerative Colitis

    Fingerprint

    Dive into the research topics of 'Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease'. Together they form a unique fingerprint.

    Cite this